Recipients, donors, and CBT characteristics with available CBU samples, HLA-HR data, and according to CTLA4-CBU genotyping (n = 305)
| Recipients . | AA-CBU genotyping, n = 73 . | AG-CBU genotyping, n = 153 . | GG-CBU genotyping, n = 79 . |
|---|---|---|---|
| Male sex, n | 32 | 93 | 51 |
| Age, median (range), y | 13 (0.7-56) | 13 (0.8-60) | 11 (0.7-48) |
| Weight, median (range), kg | 39 (7-93) | 50 (7-112) | 36 (6-94) |
| Children ≤18 y, n | 45 | 91 | 55 |
| Positive CMV serology, n | 43 | 91 | 46 |
| Major ABO incompatibility, n | 13 | 49 | 29 |
| Diagnostic, n | |||
| ALL | 36 | 82 | 42 |
| AML | 28 | 57 | 24 |
| MDS | 9 | 14 | 13 |
| HLA compatibility, n | |||
| 8/8 | 5 | 8 | 2 |
| 7/8 | 9 | 17 | 14 |
| 6/8 | 18 | 40 | 18 |
| 5/8 | 21 | 45 | 32 |
| 4/8 | 13 | 34 | 12 |
| 3/8 | 7 | 9 | 1 |
| Disease status at time of CBT, n | |||
| Early | 32 | 66 | 27 |
| Intermediate | 28 | 56 | 30 |
| Advanced | 13 | 31 | 22 |
| GVHD prophylaxis, n | |||
| CsA ± others | 68 | 137 | 71 |
| MTX ± others | 4 | 9 | 3 |
| Others | 0 | 2 | 3 |
| Use of ATG and /or monoclonal antibody, n | |||
| Yes | 8 | 9 | 9 |
| No | 62 | 139 | 68 |
| Infused TNC dose, median (range), ×107/kg | 3.7 (1-17) | 3.4 (1-19) | 3.9 (1-20) |
| Infused CD34+ cell dose, median (range), ×105/kg | 1.8 (0.3-18) | 1.7 (0.2-9) | 1.6 (0.3-17) |
| Follow-up (range), mo | 59 (4-125) | 60 (3-145) | 40 (6-86) |
| Recipients . | AA-CBU genotyping, n = 73 . | AG-CBU genotyping, n = 153 . | GG-CBU genotyping, n = 79 . |
|---|---|---|---|
| Male sex, n | 32 | 93 | 51 |
| Age, median (range), y | 13 (0.7-56) | 13 (0.8-60) | 11 (0.7-48) |
| Weight, median (range), kg | 39 (7-93) | 50 (7-112) | 36 (6-94) |
| Children ≤18 y, n | 45 | 91 | 55 |
| Positive CMV serology, n | 43 | 91 | 46 |
| Major ABO incompatibility, n | 13 | 49 | 29 |
| Diagnostic, n | |||
| ALL | 36 | 82 | 42 |
| AML | 28 | 57 | 24 |
| MDS | 9 | 14 | 13 |
| HLA compatibility, n | |||
| 8/8 | 5 | 8 | 2 |
| 7/8 | 9 | 17 | 14 |
| 6/8 | 18 | 40 | 18 |
| 5/8 | 21 | 45 | 32 |
| 4/8 | 13 | 34 | 12 |
| 3/8 | 7 | 9 | 1 |
| Disease status at time of CBT, n | |||
| Early | 32 | 66 | 27 |
| Intermediate | 28 | 56 | 30 |
| Advanced | 13 | 31 | 22 |
| GVHD prophylaxis, n | |||
| CsA ± others | 68 | 137 | 71 |
| MTX ± others | 4 | 9 | 3 |
| Others | 0 | 2 | 3 |
| Use of ATG and /or monoclonal antibody, n | |||
| Yes | 8 | 9 | 9 |
| No | 62 | 139 | 68 |
| Infused TNC dose, median (range), ×107/kg | 3.7 (1-17) | 3.4 (1-19) | 3.9 (1-20) |
| Infused CD34+ cell dose, median (range), ×105/kg | 1.8 (0.3-18) | 1.7 (0.2-9) | 1.6 (0.3-17) |
| Follow-up (range), mo | 59 (4-125) | 60 (3-145) | 40 (6-86) |
This cohort is a subset of recipients with available CBU (n = 696).
HR-HLA, high-resolution HLA. Other abbreviations are explained in Table 1.